Home » Newsletters » BioWorld Science

BioWorld Science

April 19, 2021

View Archived Issues

Carrimycin studied in phase III to treat severe COVID-19 in hospitalized patients

GlaxoSmithKline begins phase I/II study of influenza vaccine candidate GSK-3206641A

Phase III study of chiauranib in SCLC begins

First patients treated in phase I/II trial of pyrilutamide for acne in China

NMPA of China approved IND application for HLX-26

BOLD-100 shows robust preclinical efficacy against COVID-19 variants

New PROTAC induces degradation of hematopoietic prostaglandin D synthase

Optimization of indolinylpyrimidine derivatives to obtain potent orally bioavailable GPR119 agonists

Transcenta begins phase I evaluation of TST-001 with CAPOX for gastric cancer

Phase I study of eryaspase in first-line pancreatic cancer escalates to next cohort

Beijing Jacobio Pharmaceuticals divulges new KRAS inhibitors

FDA approves Nextstellis for prevention of pregnancy

Nanjing TransThera Biosciences patents PADI4 inhibitors

Medshine Discovery presents new BTK inhibitors

Shenzhen Targetrx Biotechnology synthesizes Ret inhibitors

New MISRI-targeting antibodies presented by French researchers

U.S. approval for Opdivo with chemotherapy for advanced gastric cancers

Autotaxin inhibitor BIO-32546 for neuropathic pain

Loxo Oncology presents next-generation RET inhibitor candidates

Discovery of EU-129 for treatment of severe COVID-19 in patients with underlying diseases

SYD-1875 shows promising antitumor activity in PDX models of multiple tumor types

European Commission approves Sarclisa with Kd for relapsed multiple myeloma

BerGenBio updates progress from phase II studies of bemcentinib in COVID-19

FDA clears IND for phase IIa study of naptumomab estafenatox in NSCLC

Biond opens phase I/II trial of BND-22 in advanced solid tumors

Brain injury modulates bone marrow cells to reduce neuroinflammation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...